A phase Ib trial of NSI-189 for treatment of cognitive deficit in schizophrenia
Latest Information Update: 28 Feb 2022
At a glance
- Drugs NSI 189 (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Palisade Bio; Seneca Biopharma
Most Recent Events
- 09 Nov 2015 According to a Neuralstem media release, this trial is expected to start in 2016.
- 19 Mar 2015 New trial record